Latest News

Roche licences antiviral nucleoside from Atea

Antiviral drugs are hoped to eliminate the novel Coronavirus right from the beginning of infection and thus ameliorate severe courses of COVID-19. Besides nucleoside analogues, blockers of the highly conserved viral main protease or antibodies that target the spike protein are under clinical development. © Roche


by tg

Roche AG has paid US$350 in cash to co.develop and market Atea Pharmaceutical’s oral direct-acting antiviral, AT-527, to limit proliferation of SARS-CoV-2.

Under the agreement, Roche will pay US$350m in cash for ex US-distribution of Atea Pharmaceuticals antiviral Phase II candidate. Atea has the option to co-market the drug with help of the pharma giant’s US disttribution network.

AT-527 is an investigational, oral, purine nucleotide prodrug, which has demonstrated in vitro and in vivo antiviral activity against several enveloped single-stranded RNA viruses, including human flaviviruses and coronaviruses. The prodrug was designed to uniquely inhibit viral RNA dependent RNA polymerase, an enzyme that is essential for the replication of RNA viruses. Antiviral activity and safety of AT-527 has been demonstrated in Phase II clinical studies of hepatitis C patients, and in preclinical in-vitro assays with SARS-CoV2 virus. Currently the drug cancidate is being tested in a Phase II study in hospitalised patients with moderate COVID-19 course. The plan is to enter pivotal Phase III studies In Q1/2021. AT-527 is not yet licensed or approved for any indication in the United States or any other country.

LSP reports first closing of dementia fund

The LSP Dementia Fund is the first fund globally dedicated to fight neurodegenerative diseases with help of drug and medtech solutions. The fund will...

Immunocore bags US$75m in Series C round

The round included support from existing investors and funds and accounts managed by BlackRock. Immunocore said it will use the proceeds to ...

Novo Holdings creates Hemab

Hemab ApS will combine antibody know-how from Genmab A/S and Novo Nordisk to fight medically underserved orphan bleeding disorders.  The company...

BI initiates Phase II testing of COVID-19 drug

A new potential weapon against severe complications such as ARDS caused by the new coronavirus SARS-CoV-2 have been advanced by Boehringer Ingelheim...

3,000+ experts discuss bioeconomy globally

First editions of the summit took place in Berlin in 2015 and 2018.   This year, due to the pandemic, it is not taking place in Berlin as...

Avantium NV bags money for demo plant

The new grant is part of a €30m financing mix that Avantium and the Groningen consortium announced this January. FDCA is the key building block for...

3P Bio to manufacture SpyBiotech vaccine

Under the agreement, Navarra-based CDMO 3P Biopharmaceuticals will produce cGMP lots for Phase I testing of SpyBiotech’s (Oxford) vaccine candidate...